Merck is trading higher following a positive session for the broader pharmaceutical sector, where peers like Moderna and Bristol-Myers Squibb both saw gains of 4.6% in the prior regular session. This momentum follows recent news that Merck is advancing its oncology pipeline, including the presentation of pivotal phase 3 results at ESMO 2026 and ongoing collaboration efforts with Moderna on cancer vaccine manufacturing and commercialization. While the company faces negative sentiment regarding projected earnings declines and a recent 60% cut to the peak sales forecast for its experimental eye treatment remigromig, investors appear to be prioritizing the company's defensive characteristics and pipeline progress as it heads toward its October 29 earnings release.